Lupin launches Bromfenac Ophthalmic Solution

09 Jan 2024 Evaluate

Lupin has launched Bromfenac Ophthalmic Solution, 0.07%, after having received an approval from the United States Food and Drug Administration (USFDA). Lupin is the exclusive first-to-file for this product and is eligible for 180-day exclusivity.

Bromfenac Ophthalmic Solution, 0.07% is the generic equivalent of Prolensa Ophthalmic Solution, 0.07%, of Bausch & Lomb Inc. It is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Bromfenac Ophthalmic Solution (RLD Prolensa) had estimated annual sales of $182 million in the U.S. (IQVIA MAT November 2023). 

Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.


Lupin Share Price

1626.90 -33.05 (-1.99%)
21-May-2024 09:32 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1527.00
Dr. Reddys Lab 5799.90
Cipla 1407.00
Zydus Lifesciences 1133.00
Lupin 1626.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.